| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | -0.083 | 0.01 |
| mRNA | WP1130 | CTRPv2 | pan-cancer | AAC | -0.083 | 0.02 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.077 | 0.02 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | -0.072 | 0.02 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | -0.073 | 0.02 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.069 | 0.02 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | -0.08 | 0.02 |
| mRNA | selumetinib:JQ-1 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.078 | 0.02 |